Single Institution Experience with Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)
Introduction: Neuroendocrine tumors (NETs) are a rare and heterogenous group of tumors with rising incidence. Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogue is an encouraging systemic treatment modality with minimum side effects.
Aim(s): To present our initial experience with PRRT since FDA approval in January 2018 in patients with NET and other somatostatin receptor (SSTR) positive tumors.
Materials and methods: Sixty-one patients with progressing NETs (32 pancreas, 17 small intestine, 1 coecum, 1 gastric, 5 of unknown primary), 3 paragangliomas, and 2 pheochromocytomas underwent PRRT with 177Lu-labeled Dotatate at our institution. 68Ga-Dotatate PET/CT was performed at baseline, after 2 cycles, and following completion of treatment. RECIST and SSTR density based on change of SUVmax were used to evaluate response to therapy. Laboratory tests were obtained at baseline and 1 week before each cycle and every 2 months at follow up. Progression-free survival (PFS), objective response rate (ORR) and toxicity were assessed. Considering the short follow-up time, an interim overall survival (OS) analysis was performed.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Duan H
To read the full abstract, please log into your ENETS Member account.